Precarious hope: Ethical considerations for offering experimental fetal therapies outside of research after initial studies in humans
Prenatal Diagnosis · 2024-02 · 44 (2) · 180-186
DOI: 10.1002/pd.6474 ↗At a glance
Journal article in Prenatal Diagnosis, published online on 2023-12-09. Written by Saskia Hendriks and 8 co-authors. Institution: Department of Bioethics, NIH Clinical Center, Bethesda, Maryland, USA. Major MEDLINE topics: Prenatal Care, Fetal Therapies. Cited 12 times so far (Crossref); 52 references. The full text is freely available in PubMed Central. Funded by: NICHD NIH HHS, Intramural NIH HHS, NIH HHS.
Abstract (original language)
Objective
Risks and benefits of experimental fetal therapies can remain uncertain after initial clinical studies, especially long‐term effects. Nevertheless, pregnant individuals may request them, hoping to benefit their future child. Guidance about offering experimental fetal therapies outside research (as “innovative therapy”) is limited, despite their ethical complexity. We propose points for clinicians and reviewers to consider when deciding whether and how to offer experimental fetal therapies as innovative therapies after initial clinical studies.
Method
We used conceptual analysis and a current case to develop points for consideration, grounded in broader debates on innovative therapy and the unique challenges associated with experimental fetal therapies.
Results
Clinicians should evaluate whether offering experimental fetal therapies as innovative therapy is appropriate for a pregnant individual and their fetus. The anticipated risk‐benefit ratio for the fetus should be favorable. For the pregnant individual, risks may outweigh benefits, within reasonable limits. Medical resources should be sufficient to ensure appropriate care. Clinicians should support pregnant individuals in making informed choices. Clinicians offering innovative therapies with more than minimal risk should collect and report data on outcomes. Independent review should take place.
Conclusion
Considering these points may advance the interests of fetuses, future children, and their families.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Bioethics, NIH Clinical Center, Bethesda, Maryland, USA.
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland, Baltimore, Maryland, USA.
- Department of Pediatrics, Division of Nephrology, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Gynecology and Obstetrics, Center for Fetal Therapy, Johns Hopkins University, Baltimore, Maryland, USA.
- National Human Genome Research Institute, Bethesda, Maryland, USA.
Funding
- NICHD NIH HHS
- Intramural NIH HHS
- NIH HHS
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Cite
APA
Hendriks, S., Althaus, J., Atkinson, M. A., Baschat, A. A., Berkman, B. E., Grady, C., Wasserman, D., Wendler, D., & Miller, J. L. (2024). Precarious hope: Ethical considerations for offering experimental fetal therapies outside of research after initial studies in humans. Prenatal Diagnosis, 44(2), 180-186. https://doi.org/10.1002/pd.6474
Vancouver
Hendriks S, Althaus J, Atkinson MA, Baschat AA, Berkman BE, Grady C, et al. Precarious hope: Ethical considerations for offering experimental fetal therapies outside of research after initial studies in humans. Prenatal Diagnosis. 2024;44(2):180-186. doi:10.1002/pd.6474
BibTeX
@article{Hendriks2024,
author = {Hendriks, Saskia and Althaus, Janyne and Atkinson, Meredith A and Baschat, Ahmet A and Berkman, Benjamin E and Grady, Christine and Wasserman, David and Wendler, David and Miller, Jena L},
title = {Precarious hope: Ethical considerations for offering experimental fetal therapies outside of research after initial studies in humans},
journal = {Prenatal Diagnosis},
year = {2024},
volume = {44},
number = {2},
pages = {180--186},
doi = {10.1002/pd.6474}
}
EUVIMED